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ABSTRACT
Downstream in-frame start codons produce amino-
terminal-truncated human constitutive androstane
receptor protein isoforms (NCARs). The NCARs
are expressed in liver and in vitro cell systems
following translation from in-frame methionine AUG
start codons at positions 76, 80, 125, 128, 168 and
265 within the full-length CAR mRNA. The resulting
CAR proteins lack the N-terminal DNA-binding
domain (DBD) of the receptor, yielding NCAR
variants with unique biological function. Although
the NCARs maintain full retinoid X receptor alpha
(RXRa) heterodimerization capacity, the NCARs
are inactive on classical CAR-inducible direct
repeat (DR)-4 elements, yet efficiently transactivate
a DR-1 element derived from the endogenous
PPAR-inducible acyl-CoA oxidase gene promoter.
RXRa heterodimerization with CAR1, CAR76 and
CAR80 isoforms is necessary for the DR-1 PPRE
activation, a function that exhibits absolute depen-
dence on both the respective RXRa DBD and CAR
activation (AF)-2 domains, but not the AF-1 or AF-2
domain of RXRa, nor CAR’s DBD. A new model of
CAR DBD-independent transactivation is proposed,
such that in the context of a DR-1 peroxisome
proliferator-activated response element, only the
RXRa portion of the CAR-RXRa heterodimer binds
directly to DNA, with the AF-2 domain of tethered
CAR mediating transcriptional activation of the
receptor complex.
INTRODUCTION
CAR (NR1I3) is a member of the nuclear receptor
superfamily, comprised of 48 members in humans (1).
The structural features of CAR include a clearly identiﬁ-
able DNA-binding domain (DBD) but the lack of a
conventional amino-terminal AF-1 motif found in most
other nuclear receptors (2). While nuclear receptors are
typically activated by chemical ligands, CAR maintains
a high constitutive activity, limited by the cytosolic
subcellular localization of the unactivated protein (3).
CAR appears to be retained in a cytoplasmic complex
with phosphatase 2A (PP2A), heat shock protein 90
(Hsp90) (4) and a cytosolic CAR retention protein,
termed CCRP (5). Ligand and non-ligand activators,
such as 6-(4-chlorophenyl)imidazo[2,1-b]thiazole-5-
carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO) (6)
and phenobarbital, respectively (3), induce CAR
cytoplasmic-to-nuclear translocation through a pathway
involving an okadaic-acid-sensitive phosphatase (3,7).
Early studies with CAR revealed that certain andros-
tane derivatives bind directly to the receptor and function
to inhibit its transactivation. These repressive ligands
were termed ‘inverse agonists’ (8). Furthermore, inverse
agonist-bound CAR can be reactivated by exposing
the receptor complex to speciﬁc inducer chemicals
(9,10), such as, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene
(TCPOBOP), a ligand activator of mouse CAR (11); and
CITCO, the human CAR-speciﬁc agonist ligand (6).
CAR targets include genes encoding phase I and phase
II drug metabolizing functions as well as drug transport
genes [reviewed in (12)]. The target gene promoters often
contain consensus DNA response elements including
direct repeat (DR)-2 (13), DR-3, DR-4 (14), DR-5 (2)
and everted repeat (ER)-6 or ER-8 (15) motifs. CAR may
bind the DNA response elements as a monomer or as a
heterodimer with retinoid X receptor alpha (RXR)
(15,16). In some cases, at least two separate elements
may cooperate in a single gene promoter to further
enhance CAR/RXR-mediated transcriptional activation
(17,18). Like many nuclear receptors, CAR-mediated
transactivation also depends on its association with
*To whom correspondence should be addressed. Tel: 814-863-1625; Fax: 814-863-1696; Email: cjo10@psu.edu
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.nuclear co-regulator proteins, including the co-activators,
GRIP-1 (19), SRC-1 (20) and PGC-1 (21).
In addition to the reference form of human CAR,
termed CAR1, we and others have characterized alter-
natively spliced CAR transcripts that exist in human
tissues (22–24). At least one of these CAR variants,
CAR3, possesses the unique biological property of being
a ligand-activated receptor, in contrast to the constitu-
tively active nature of CAR1 (14). The results presented
in the current investigation extend the complexity of
CAR regulation by demonstrating that the receptor’s
expression is post-transcriptionally modulated through
the use of internal translation start sites, resulting in the
generation of truncated CAR proteins with altered
biological function. Our data also suggest a new model
for CAR–DNA interaction, whereby RXRa binds directly
to a DR-1 peroxisome-proliferator-activated response
element (PPRE) as a heterodimer with tethered CAR,
such that only RXRa makes direct DNA contact, with




COS-1 African green monkey kidney epithelial cell line
(ATCC, Manassas, VA) was cultured in Dulbecco’s
Modiﬁed Eagle Medium (Invitrogen, Gaithersburg, MD)
plus 10% fetal bovine serum, 1.5g/l sodium bicarbonate,
HEPES, L-glutamine and penicillin–streptomycin.
5a-Androstan-3a-ol (androstanol) and 9-cis-retinoic acid
(RA) (Sigma, St. Louis, MO), CITCO (BioMol, Plymouth
Meeting, PA), and Wyeth 14643 were dissolved in
dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO).
Enriched primary human hepatocyte cultures plated on
collagen were obtained through the Liver Tissue
Procurement and Distribution System, Pittsburgh,
funded by NIH Contract #NO1-DK-9-2310. Cells were
placed in fresh William’s E media containing: 1%
penicillin–streptomycin, 1% HEPES, 20mM glutamine,
25nM dexamethasone, 10nM insulin, 1% linoleic acid/
BSA, 5ng/ml selenious acid and 5mg/ml transferrin and
overlayed mL BD Matrigel
TM/mL BD Matrigel
TM
Basement Membrane Matrix (BD Biosciences, San Jose,
CA), as described previously (25). Adenovirus expressing
human CAR was produced using a commercially available
system AdEasy (Stratagene, Cedar Creek, TX). Primary
hepatocytes from one individual were infected with
Adenovirus-CAR (Adv-CAR) for 24h, cells were scraped
in Laemmli’s loading buﬀer and a small aliquot was
resolved by SDS-PAGE, transferred to PVDF membrane
and CAR detected by immunoblotting. Lentiviral expres-
sion plasmids, pCDH1-MCS1-EF1-copGFP and pSIH1-
H1-copGFP, and packaging plasmid mix, pPACKH1,
were purchased from System Biosciences (Mountain View,
CA). Production of lentiviral particles and subsequent
infection of target cells were performed essentially
according to the manufacturer’s protocols, except that
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was
used for transfection of HEK-293T packaging cells.
Pseudoviral supernatant harvested from the packaging
cells was either used directly for target cell infection or was
concentrated prior to infection by 10% PEG-8000 (Sigma,
St. Louis, MO) precipitation. Primary human hepatocytes
were infected with equal volumes of appropriate lentiviral
supernatant in the presence of 6mg/ml polybrene (Sigma,
St. Louis, MO), and media was replaced the following
day.
Oligonucleotides and plasmids
Oligonucleotides and PCR primers were synthesized by
Integrated DNA Technologies (IDT) (Coralville, IA).
PCR primers and EMSA oligonucleotides used are listed
in Supplementary Data. A consensus DR-4 probe used in
EMSA competition experiments contained the NR1
sequence from CYP2B6 PBREM and the sense strand
contained the classical DR-4 element AGTTCA(N)4
AGTTCA. Reporter plasmids contained four copies of
the rat acyl-CoA-oxidase (rAox) PPRE (26), a PCR
fragment from rat cellular retinol-binding protein II
promoter (rCRBPII) (27) and three copies of an optimized
AGTTCA DR-4(14). Complementary oligonucleotides
were annealed, phosphorylated and inserted in the SmaI
site of ptk-Luc, derived from pGL3-Basic vector
(Promega, Madison, WI), which was modiﬁed by insertion
of the minimal thymidine kinase (tk) element from
pBLCAT. prAox-1198/-463-tk-Luc contains a single
copy of the PPRE (DR-1: tgacctttgtcct) in its endogenous
context, encompassed by the region between  1198 and
 463bp upstream of the rAox gene transcription start site
and was ampliﬁed using rat genomic DNA as a template.
Primer sequences employed were as previously described
(28), but with slight modiﬁcations; the sense primer
(50-GGT ACC GGT ACC CCA GTA GAA CCT TGT
TCA GG-30) and antisense primer (50-GGT ACC GCT
AGC CAG GGT CTC GGG CGG AGT GAA G-30)
contained the underlined KpnI and NheI restriction
enzyme sites, respectively. The 754-bp amplicon was gel-
puriﬁed, restriction enzyme digested, gel-puriﬁed and
ligated into the ptk-Luc vector (Promega, Madison, WI).
Plasmids were prepared using QIAﬁlter Plasmid Maxi Kit
(Qiagen, Valencia, CA) and sequenced.
Coupled invitro transcription translation
Rabbit reticulocyte lysate and wheat germ expression
systems were used essentially according to the manufac-
turer’s (Promega, Madison, WI) protocols. DNA
templates were in the form of plasmids containing
CAR-coding sequence downstream of T7 promoter,
or PCR products of T7 promoter-tagged CAR fragments.
In some experiments, [
35S]methionine (ICN) was incorpo-
rated, while in other experiments a polyclonal antibody
against human CAR (23) was used to perform western
blotting.
Western-immunoblotting analysis
Cells were harvested directly in 1  Laemmli’s loading dye
and boiled for 5min. Alternately, cells were scraped in
radioimmunoprecipitation assay (RIPA) buﬀer, protein
concentrations were measured by Bradford method,
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(BioRad, Hercules, CA). For western blots examining
expression of endogenous CAR variants in primary
human hepatocytes, the cells from four diﬀerent human
donors were cultured as described above, harvested by
scraping in Trizol reagent (Invitrogen, Carlsbad, CA) and
protein samples were isolated according to the extended
manufacturer’s protocol. One-hundred and ﬁfty micro-
grams of total protein were dissolved in loading buﬀer and
were resolved by SDS-PAGE and separated proteins were
transferred to PVDF membrane (BioRad, Hercules, CA),
then probed with primary antibodies against human
CAR (generated in our laboratory) or RXRa (D-20)
(Santa Cruz). Secondary antibody goat–anti-rabbit-IgG-
HRP (Santa Cruz Biotechnology, Santa Cruz, CA) was
used at 1:5000 dilution. Blots were exposed to LumiLight
chemiluminescent substrate (Roche Applied Science,
Indianapolis, IN) and placed on autoradiography ﬁlm
(American X-Ray & Medical Supply, Sacramento, CA).
PVDF membrane was stained with Ponceau S in dilute
acetic acid and brieﬂy washed in de-ionized water until
distinct protein bands could be distinguished. Pink-stained
blots were scanned and images were changed to grayscale
for publication.
Transient transfections
p(NR1)5-Tk-Luc and pCMV-Renilla expression plasmid
(Invitrogen, Carlsbad, CA) (for normalization of transfec-
tion eﬃciency) and pCDNA3.1-CAR expression plasmids
were transiently transfected into COS-1 cells using
Fugene6 (Roche Applied Science) for 12–24h.
Transfection cocktails were prepared essentially according
to the manufacturer’s recommendations, except that
1  phosphate-buﬀered saline (PBS) was substituted for
serum-free medium in the transfection cocktail. Cells
were harvested with 50ml1   passive lysis buﬀer
(Promega, Madison, WI) and soluble protein was
extracted and assayed for luciferase activity using
Stop-‘N’-Glow system (Promega) and dual auto-inject
luminometer (Turner Biosystems, Sunnyvale, CA). Assay
reagents were diluted 1:1 with Tris-buﬀered saline and
25ml of each reagent was used to measure Fireﬂy and
Renilla luciferase activity in 40ml of cell lysate.
Experiments were repeated at least two times and
representative results are shown as mean standard
error for three or four replicates per treatment group.
Preparation of COS-1cell nuclearextracts
Nuclear extracts were prepared as described (29). Brieﬂy,
transfected COS-1 cells were harvested in 1  Promega
lysis buﬀer and allowed to swell on ice for 15min,
centrifuged at 14000 g for 1min at room temperature,
and a pellet containing crude nuclei was isolated.
Approximately ﬁve pellet volumes of 1  lysis buﬀer
supplemented with 500mM KCl (high-salt buﬀer) were
added to the pellet and further incubated on ice for 30min
to 1h with frequent vortexing. Nuclei in high-salt buﬀer
were centrifuged at 14000 g for 1min at room tempera-
ture, and aliquots of nuclear proteins in supernatant were
stored at  808C for use in EMSA.
Electrophoretic mobility shift assays (EMSAs)
A 20–30ml EMSA reaction mixture contained
 75–150mM KCl (a balance of low-salt and high-salt
buﬀers used in the nuclear extraction protocol),  5mgo f
crude nuclear protein, 1mg poly(dI-dC) (Roche Molecular
Biochemicals, Indianapolis, IN), with or without unla-
beled competitor oligonucleotide and 10–100-fmol-labeled
probe. Oligonucleotides were end labeled by incubation
with T4-polynucleotide kinase (Promega, Madison, WI)
and [g
32P]-ATP (ICN/MP Biomedicals, Solon, OH).
Reactions were incubated at room temperature for
15min and protein–DNA complexes were resolved by
5% PAGE and speciﬁc DNA–protein complexes were
observed as more slowly migrating complexes in the gel.
Gels were dried under vacuum and exposed to X-ray ﬁlm.
CAR immunofluorescence microscopy
Cells were grown on Lab-Tek 4-well chamber slides
(Nunc, Naperville, IL) and ﬁxed in  208C methanol,
air-dried, then permeabilized and rehydrated in PBS
supplemented with 0.3% Tween-20 (PBS-Tween). Cells
were blocked in goat serum, washed and incubated with
rabbit polyclonal CAR antibody (1:50 dilution). Primary
antibody was washed from cells and ﬂuorescein isothio-
cyanate (FITC)-conjugated goat–anti-rabbit IgG
(CALTAG Laboratories, Burlingame, CA) diluted 1:200
in antibody dilution buﬀer was placed on the cells for 2h
at room temperature. Finally, slides were extensively
washed in PBS-Tween, blotted dry, covered with Prolong
Anti-fade mounting solution with 40,6-diamidino-
2-phenylindole (DAPI) DNA-labeling reagent (Molecular
Probes, Eugene, OR) and sealed with a coverglass.
Immunoﬂuorescence of CAR protein was observed with
a Nikon inverted ﬂuorescence microscope (Nikon USA,
Melville, NY). Image capture was performed with SpotRT
software and digital camera (Diagnostic Instruments,
Sterling Heights, MI).
Real-time PCRmethods and dataanalysis
RNA was isolated from primary human hepatocytes using
TRIzol Reagent (Invitrogen, Carlsbad, CA) and con-
verted to cDNA using High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA), both according to
the manufacturer’s protocols. Real-time PCR was per-
formed using Assays-on-Demand Gene Expression
Products (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s instructions, with minor
modiﬁcations and run on an ABI 7300 Real-time PCR
System (Applied Biosystems). Real-time PCR data were
analyzed using the CT method (30).
RESULTS
Initial identification of truncated CAR proteins
Primary human hepatocytes express multiple nuclear
receptors. In Figure 1A, we present results from western
immunoblot assays performed on whole-cell extracts
derived from primary hepatocytes of four individual
human donors, using rabbit polyclonal antibodies directed
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Multiple protein bands were detected for CAR. At least
three immunoreactive CAR bands were observed. One
CAR product migrated at the predicted molecular weight
of the full-length protein ( 37kDa). A second prominent
immunoreactive band displayed an apparent molecular
weight in excess of 25kDa and a third band migrated at
 20kDa. Similar results were obtained with protein
extracts analyzed from liver tissues of other indivi-
duals (23). The CAR immunoreactive bands detected
co-migrated with positive control extracts from HEK-
293T cells transfected with expression plasmids for CAR1
and CAR76 that were run concurrently. Known splice
variants of CAR include CAR2, containing a four amino
acid (4 aa) insertion (SPTV) between exons 6 and 7;
CAR3, which possesses a 5 amino acid (5 aa) insertion
(APYLT) between exons 8 and 9; a transcript including
insertion of both SPTV and APYLT (DBL); and a variant
possessing a partial deletion of exon 7 (7), that results in
the loss of 39 aa from the ligand-binding domain of CAR
(23). Each of these variant proteins is therefore predicted
to migrate well above the  25kDa range. In COS-1 cells
transiently transfected with expression plasmids for CAR
and CAR splice variants, multiple immunoreactive CAR
products of similar molecular mass were also observed
in western immunoblot assays, conducted using an anti-
body directed against the carboxyl-terminus of CAR
(Figure 1B).
We performed computer alignments using the ClustalW
tool (http://www.ebi.ac.uk/clustalw/) (31) to demonstrate
the conservation of human, mouse and rat CAR mRNA
sequences (Figure 2A). The numbers indicated above the
sequences are relative to the predicted initial start of
translation at codon 1 in the human sequence. Numbers to
the right denote relative sequence within the coding exons
of CAR. It should be noted that mouse and rat CAR
include 30 extra nucleotides, coding for 10 additional
amino-terminal amino acids as compared with human
CAR, such that codon 76 in human CAR equates to
codon 86, etc., in mouse/rat CAR, respectively. The
alignments of (human) codons 76 and 80 were most highly
conserved across species, while more variability existed for
A
B
Figure 1. Western immunoblot analyses. (A) Expression of CAR-
variant proteins and RXRa protein in human primary hepatocytes
from four donors. Lanes 1–4, 150mg whole-cell protein extract from
each of four donors; lanes 5 and 6 are positive control whole-cell
protein extracts from HEK-293T human embryonic kidney cell lines
transfected with expression plasmids for CAR 1 or CAR 76 and treated
with 1mM MG-132 proteasome inhibitor to augment CAR expression.
Ponceau S staining was performed to indicate total protein loading in
each lane. (B) CAR protein expression in COS-1 cells transiently
transfected with CAR and CAR splice variant expression plasmids.
Lane 1, empty vector transfection (V); lane 2, CAR wild-type (WT);
lane 3, CAR4aa (SPTV amino acids inserted between exons 6/7);
lane 4, CAR5aa (APYLT amino acids inserted between exons 7/8);
CAR-DBL (four and ﬁve amino acid insertion); and CAR7 (partial
deletion of exon 7 coding for 39 amino acids). Embedded asterisks
denote unexpected lower molecular weight CAR products.
A
B
Figure 2. ClustalW alignment of human, mouse and rat CAR mRNA
sequences. (A) Numbers above sequences denote NetStart1.0-predicted
in-frame internal protein translation start sites. Numbers above
sequences represent codon numbering based on human sequence.
Numbers listed to the side indicate relative position of nucleotides
within coding sequence, asterisks denote sequence conservation across
species. (B) CAR protein and mRNA sequences alignment. Predicted
CAR translation start sites are denoted by arrows at 1, 76, 80, 125, 128,
168 and 265. For full-length CAR protein, translation begins from a
start codon 1 in exon 2 and continues to codon 348 in exon 9.
2180 Nucleic Acids Research, 2007, Vol. 35, No. 7codons 125 and 128. The human CAR-coding sequence
was analyzed with the web tool, NetStart 1.0 (http://
www.cbs.dtu.dkservices/NetStart) (32) to predict internal
protein translation start sites on a 0–1.0 scale. A call of 0.5
or higher was assigned by the program as a high-
probability translation start site. Codon 125 is included
in the ﬁgure as well, as it scored close to 0.5, within the
0.4–0.5 range. In Figure 2B, a simple alignment of human
CAR protein and exons was performed and revealed that
all potential internal translation start sites remove the
amino-terminal (N-terminal) DBD of the receptor, and
that most fall in the exon 3–5 region. Therefore,
subsequent analyses were focused on the less severely
deleted variants, arising from potential translation start
sites at codons 76, 80, 125, 128 and 168.
Truncated CAR proteins transactivate aDR-1 PPRE
To quickly test whether predicted downstream and
in-frame AUG start codons in CAR would drive trans-
lation of shorter protein products, the ﬁrst AUG was
mutated to AAG, to produce a lysine (K) instead of
methionine (M) at position 1, and the derived construct
was termed CAR M1K. Assuming CAR mRNA is
translated to protein by a ‘cap-dependent’ scanning
ribosome process, there is an expectation that increased
translation would then occur from the use of downstream
AUG start sites in the CAR M1K template. Results
presented in Figure 3A clearly show that overexpression of
CAR1 by Adv-CAR-mediated infection of primary
cultures of human hepatocytes, or expression of CAR1
and CAR M1K mutant in wheat germ lysates, produced
multiple protein products as detected by immunoblotting
with an antibody designed against the C-terminus of
CAR. In lanes 1 and 3, major CAR products were
observed in close alignment with the 37kDa, and between
the 25 and 37kDa markers, respectively. In lane 4,
introduction of the M1K mutation resulted in a dramatic
increase in the expression of truncated CAR protein, likely
from initiation at one or both of the codons 76 and 80.
The very low level of apparent full-length CAR in the
CAR M1K lane was not observed in subsequent experi-
ments, but in this overexposed ﬁlm the band may have
arisen from use of the less common internal translation
start at leucine/codon 8, or more likely from slight spill-
over from the CAR1 lane during gel loading. Once it was
established that CAR M1K expression resulted in expres-
sion of truncated protein products, the potential tran-
scriptional activities of the variant proteins were tested in
transient transfection assays, using assorted, previously
identiﬁed nuclear receptor consensus response elements.
We hypothesized that the truncated forms of CAR may
exert dominant negative or enhanced activity on speciﬁc
elements. Previous studies in this and other laboratories
demonstrated that CAR1 primarily activates reporter
genes driven by DR-4 or DR-5 elements (2,14), and
exhibits particularly strong activation of a DR-4 that
contains the perfect half-site AGTTCA (15). In our initial
transient transfection assays, we screened a number of
potential response elements for activity of CAR1 and
CAR M1K in COS-1 cells. Surprisingly, CAR1 and CAR
M1K similarly activated the special DR-1 element, rAox
PPRE, containing the sequence (TGACCT(N)1TGT
CCT), as well as an element containing a series of DR-1
motifs derived from the rCBPII promoter, where CAR
M1K exhibited greater responsiveness than did CAR1
(Figure 3B). These marked transcriptional activation
responses were dependent on the presence of
co-transfected RXRa and also exhibited apparent cell
line dependency, as they were retained in HepG2 and
COS-1 cells but not readily detected in HuH7, A549,
Hepa1c1c7, HEK-293A or MCF-7 cells (data not shown).
A
B
Figure 3. Western immunoblot assay. (A) CAR full-length protein
and translational variants are expressed in Adv-CAR-infected
human hepatocytes and in in vitro wheat germ expression system.
Lane 1, human primary hepatocytes infected with adenovirus
expressing wild-type CAR mRNA; (lanes 2–4, wheat germ lysates);
lane 2, empty vector control; lane 3, pCDNA3.1( )CAR 1; lane 4,
pCDNA3.1( )CAR M1K—start methionine mutated to lysine.
Numbers to the left of ﬁgure indicate predicted internal translation
variants’ relative molecular weights (Mr). (B) CAR 1 and CAR M1K
diﬀerentially transactivate DR-4 and DR-1 elements. COS-1 cells were
transiently transfected with 100 ng of reporters p(DR-4)3-tk-Luc,
p(rCRBPII)-tk-Luc or p(rAox-PPRE)4-tk-Luc, 50ng RXRa and CAR
expression plasmids and 10ng pRL-CMV.
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responses is not yet understood, however the cell selective
presence/absence of speciﬁc co-regulator proteins is likely
responsible. NCAR functional characterization studies
were continued in COS-1 cells since these cells were
markedly activated in a highly reproducible manner and
exhibited the highest transfection eﬃciencies of all the cell
lines tested.
NCARs activate transcription in theabsence of aDBD
Given the initial success with the CAR M1K mutation and
the expression of truncated CAR proteins, we tested
whether expression of the lower molecular weight CAR
products could be ablated by mutating additional putative
downstream start codons at positions 76 and 80. Indeed,
expression of CAR M1K in wheat germ and rabbit
reticulocyte lysate systems in the presence of
[
35S]-methionine (Figure 4A) (lanes 2 and 7) resulted in
the predominant production of a lower molecular weight
species. When CAR76 template was overexpressed
(lanes 3 and 8), the product co-migrated with the protein
produced by CAR M1K, suggesting that codon 76 may be
a biologically relevant internal translation start site
in CAR. However, expression of CAR 1,M76K (lanes 4
and 9) revealed that mutation of codon 76 alone, in the
context of the full-length template, could not abolish
the lower molecular weight product. Subsequent dual
mutation of both codons 76 and 80 in the form of CAR
1,M76K/M80K (lanes 5 and 10) completely eliminated
expression of the truncated form of CAR, supporting a
model of ribosome scanning from the 50- ‘cap’ structure
of CAR mRNA, resulting in the use of codon 80 as an
Figure 4. Truncated forms of CAR are expressed and activate transcription through a special DR-1 element. (A) SDS-PAGE of coupled in vitro
transcription/translation of [
35S]-methionine-labeled CAR in wheat germ lysate (lanes 1–5) and rabbit reticulocyte lysate (lanes 6–10). Lanes 1 and 6,
pCDNA3.1( )CAR 1; lanes 2 and 7, pCDNA3.1( )CAR M1K; lanes 3 and 8, pCDNA3.1( )CAR 76; lanes 4 and 9, pCDNA3.1( )CAR 1, M76K;
and lanes 5 and 10, pCDNA3.1( )CAR 1, M76K/M80K. (B) Diﬀerential activation of p(DR-4)3-tk-Luc and p(rAox-PPRE)4-tk-Luc by amino-
terminally truncated forms of CAR. (C) Activation of p(rAox-1198/-463)-tk-Luc, a genomic promoter fragment containing a single copy of the
PPRE element, by CAR 1 and CAR 76. COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng pCDNA3.1( ) empty vector
or pCDNA3.1( )CAR plasmids, 50ng pCDNA3.1(þ)RXRa and 10ng pRL-CMV (for transfection normalization) and assayed for luciferase activity
24–48h post-transfection.
2182 Nucleic Acids Research, 2007, Vol. 35, No. 7initiation site only when codon 76 was mutated.
In wheat germ lysate and in longer exposures of rabbit
reticulocyte lysate, even lower molecular weight
CAR products were detected, likely attributable to
further alternative translation from codons 125 and 128
(data not shown).
To test the transcriptional activity of the various CAR
constructs, COS-1 cells were transiently transfected with
p(DR-4)3-tk-Luc and p(rAox-PPRE)4-tk-Luc. CAR1 and
translational variants of CAR1 including, CAR M1K,
CAR76, CAR80, CAR125, CAR128 or CAR168, were
examined, all in the presence of co-transfected RXRa
expression plasmid (Figure 4B). In Figure 4C, CAR1 and
CAR76 activated transcription of a non-oligomerized
PPRE from the rAox gene promoter, contained in a
750-bp DNA fragment of rat genomic DNA and placed
upstream of tk-Luc. The magnitude of the response and
pattern of activation closely resembled the activation
obtained when using four copies of the PPRE upstream of
tk-Luc. To summarize the results obtained, CAR1 was
active on DR-4 and DR-1 elements, but successive
deletion of CAR protein to position 80 redirected full
activation to only the DR-1 element. When CAR
expression was forced from downstream codons, at 125,
128 and 168, the yielded proteins were without demon-
strable transactivation potential on either DR-4 or DR-1
elements.
Results detailed in Figure 5 demonstrate that CAR1
transcriptional activation of the DR-4 element is RXRa
independent and that CAR76 and CAR80 were comple-
tely inactive on this element, regardless of RXRa
co-transfection. To ascertain the extent to which CAR
could be deleted on its N-terminus and still retain
transcriptional activity on a DR-4 motif, a number of
other deletion mutants of CAR were tested (Figure 5A).
Deletion of 10 aa from the N-terminus of CAR
(CAR11) resulted in complete loss of activity, however
co-transfection of RXRa restored transactivation of
CAR11 on the DR-4 element, near to the levels seen
with CAR1. Further truncation of CAR (CAR14 to
CAR125) produced constructs that were incapable of
activating DR-4 response element-driven luciferase gene
expression. CAR11 includes the ﬁrst cysteine residue
within the ﬁrst zinc ﬁnger of the receptor; predicted to be
an important determinant for DNA binding. Surprisingly,
when the same successively deleted CAR constructs were
assayed for activity on the DR-1 element, in the presence
of excess RXRa, all the constructs—through CAR103,
maintained full transcriptional activity, while CAR113
and CAR125 were inactive (Figure 5B). Recently, the
crystal structure of CAR:RXRa was reported, derived
from a minimal CAR:RXRa dimerization interface that
included amino acids 103–348 of CAR (33). Our results
similarly suggest that proper heterodimer formation
between RXRa and CAR residues 103–348 is important
for CAR transcriptional activity on a DR-1 element.
CAR activity on DR-1PPRE is RXR-dependent
Since the ﬁrst 102 aa of CAR were dispensable for
transcriptional activity on a DR-1, we probed the
importance of other domains for this activity. We deleted
a portion of the CAR C-terminus to remove 8 aa that
contained the receptor’s AF-2 domain. The results
indicated that, even in the presence of RXRa, CAR
1iAF-2 was devoid of transcriptional activity on the
DR-1 element (Figure 6A). Although CAR activity on the
DR-1 did not require the ﬁrst third of the protein, it was
dependent on an intact AF-2 domain, as well as
co-transfected RXRa. To further delineate the RXRa-
dependent transactivation of the DR-1 by CAR and the
NCARs, a series of RXRa domain deletion constructs
were co-transfected into COS-1 cells (Figure 6B). Deletion
of RXRaDBD amino acids 135–161 resulted in a loss
of CAR1 and NCAR transcriptional activity, likely
due to the loss of RXRa’s ability to directly bind
DNA. However, deletion of the AF-1 and AF-2 functions
of RXRa, alone or in combination, had little eﬀect on
the transactivation ability of CAR1, CAR76 or CAR80
to activate the DR-1 element (Figure 6C). These results
provided additional support for the concept that
direct binding of RXRa to DNA was a necessary
component for CAR’s activity at the DR-1 element,
A
B
Figure 5. Transient transfection assays. (A) An intact DNA-binding
domain is necessary for CAR transcriptional activity on a DR-4
element. COS-1 cells were transfected with 100ng p(DR-4)3-tk-Luc,
50ng empty vector or RXRa, 50ng empty vector or CAR constructs
and 10ng pRL-CMV. (B) CAR amino acids 103–348 and
co-transfected RXRa are required for full transcriptional activity
on a DR-1 element. COS-1 cells were transfected with 100ng
p(rAox-PPRE)4-tk-Luc, 50ng empty vector or RXRa, 50ng empty
vector or CAR constructs and 10ng pRL-CMV.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2183but that CAR’s AF-2 domain provides the requisite
interaction with co-regulators.
Since RXRa homodimers bind well to DR-1 elements,
we also tested whether RXRa deletion mutants were
themselves transcriptionally active on p(rAox-PPRE)4-tk-
Luc in the presence of the RXRa ligand RA (Figure 6D).
The results obtained showed that wild-type and AF-1-
deleted RXRa were fully activated by ligand, while any
deletion of AF-2 or DBD yielded transcriptionally
inactive proteins.
Our initial data indicated that CAR or NCAR inter-
action with RXRa was necessary for CAR-mediated
transactivation through the DR-1 PPRE. Co-transfection
experiments were performed with two diﬀerent point-
mutated RXRa plasmids to demonstrate that
CAR:RXRa dimerization was absolutely required for
transcriptional activity (Figure 7A). Use of RXRa Y397A,
a mutation in the human receptor corresponding to a
well-characterized heterodimerization-deﬁcient Y402A
mutation in mouse RXRa (34), completely ablated
CAR-mediated transactivation on the PPRE. However,
this heterodimerization-mutant RXRa was still fully
functional as a homodimer after addition of RA. An
additional mutation of RXRa yielded L430F, a mutant
defective in homodimerization (35), as demonstrated here
by the lack of induction of luciferase activity in the
presence of RA. However, the L430F mutant mediated
nearly full induction of reporter activity when CAR1 was
co-transfected. Further, immunoﬂuorescence microscopy
demonstrated transfected CAR1 was expressed primarily
A B
C D
Figure 6. Transient transfection assays. (A) CAR AF-2 is required for transactivation through a DR-1 element. COS-1 cells were transfected with
100ng p(rAox-PPRE)4-tk-Luc, 50ng empty vector or RXRa, 50ng empty vector or CAR constructs and 10ng pRL-CMV. (B) CAR activation of
p(rAox-PPRE)4-tk-Luc is RXRa DNA-binding domain dependent. COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng
pCDNA3.1( ) empty vector or pCDNA3.1( )CAR plasmids, 50ng pCDNA3.1( ), pCDNA3.1(þ)RXRa or pCDNA3.1(þ)RXRaDBD and 10ng
pRL-CMV (for transfection normalization) and assayed for luciferase activity 24–48h post-transfection. (C) CAR transactivation of p(rAox-PPRE)4-
tk-Luc is independent of RXRa AF-1 and RXRa AF-2. COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng
pCDNA3.1( ) empty vector or pCDNA3.1( )CAR plasmids, 50ng pCDNA3.1( ), pCDNA3.1(þ)RXRa, pCDNA3.1(þ)RXRaAF-1 or
pCDNA3.1(þ)RXRaAF-2 and 10ng pRL-CMV (for transfection normalization) and assayed for luciferase activity 24–48h post-transfection.
(D) RXRa deletion constructs DBD- and AF-2-dependently transactivate p(rAox-PPRE)4-tk-Luc in response to RXR ligand 9-cis-retinoic acid (RA).
COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng pCDNA3.1(þ) or pCDNA3.1(þ)RXRa or RXRa domain deletion
variants and 10ng pRL-CMV (for transfection normalization) for 24h, then treated with dimethyl sulfoxide (DMSO) solvent control or 1mM
9-cis RA for 24h and assayed for luciferase activity.
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presence of co-transfected RXRa (Figure 7B). In contrast,
CAR76 and CAR80 expression was evenly distributed
between the cytoplasmic and nuclear compartments in
the absence of co-expressed RXRa, but became primar-
ily nuclear in the presence of excess RXRa. When
the RXRaY397A heterodimerization mutant was
co-expressed with CAR1, CAR76 or CAR80, the dis-
tribution of the CAR proteins was similar to results
obtained with co-transfected empty vector alone.
CAR ligands modulate variantprotein activity
CAR exhibits high constitutive activity in transfected cells,
presumably because proteins involved in cytoplasmic
sequestration of the protein in primary hepatocytes are
missing from cell lines (5). Consequently, early studies
identiﬁed so-called inverse agonists of CAR, such as
androstanol, which could repress the constitutive transac-
tivation potential of CAR (8). When CAR1 was trans-
fected with RXRa, p(DR-4)3-tk-Luc activity was highly
induced, as predicted, while CAR76 and PPARa were
inactive on this element (Figure 8A). A titration of
androstanol from 0.5 to 8 micromolar (mM) indicated
that a maximal inhibition of CAR1 constitutive activity
was achieved at  2mM. A similar androstanol treatment
was repeated on cells transfected with CAR1, CAR76, and
PPARa with p(rAox-PPRE)4-tk-Luc. A 2mM concentra-
tion of reagent produced a maximal inhibition of CAR1
and CAR76 activity and modestly raised PPARa activity
at higher concentrations (Figure 8B). Although inhibition
of PPARa activation by androstanol was not anticipated,
the eﬀect provided an internal control for the experiments
and indicated that androstanol was not simply decreasing
luciferase activity through a non-speciﬁc mechanism of
transcriptional repression. Since the truncated CAR76
and CAR80 isoforms behaved like CAR1 in the presence
of androstanol, it appears that ligand binding and
dimerization properties of CAR are maintained in the
least truncated NCARs. CAR1, 76 and 80 activities that
were decreased by androstanol treatment on the p(rAox-
PPRE)4-tk-Luc construct were restored by co-treatment
with the human CAR agonist ligand, CITCO (Figure 8C).
Titration of CITCO from 0.3 to 2.5mM revealed that
0.3mM was suﬃcient to completely antagonize the eﬀect
of 2mM androstanol treatment, and lower concentrations
of CITCO, in the range of 3–30 nanomolar (nM),
signiﬁcantly activated androstanol-repressed CAR1,
CAR76 and CAR80 transcription on the DR-1 PPRE
(data not shown).
Nocorrelation between CAR/RXRaDNA binding and
transactivation
Nuclear extracts from COS-1 cells enriched for CAR1 or
CAR76 expression (by neomycin selection of a CAR-
expressing cell population) were used to perform gel shift
assays with a [
32P]-labeled, CYP2B6-derived DR-4
element (NR1) or a [
32P]rAoxPPRE (Figure 9A). These
results demonstrated that CAR1 and CAR76 bind to both
elements, but that the interaction of CAR1 was the most
robust. Since CAR76 was not active on a DR-4 in
transient transfection assays, and CAR1 and 76 were
equally active on the rAox-PPRE DR-1 in the luciferase
assays, no obvious correlation was apparent between
DNA-binding aﬃnity in the EMSAs and the respective
reporter gene activation levels. When CAR 1 or PPARa
were expressed with RXRa in COS-1 cells, and nuclear
extracts from those cells were incubated with [
32P]NR1
DR-4 or [
32P]rAox-PPRE DR-1, CAR1 and PPARa
interacted with both DR-4 and DR-1 elements more
strongly than did RXRa alone (Figure 9B). Again, even in
the presence of excess RXRa, no direct correlation was
manifested between receptor–DNA complex formation
and transactivation of DR-4- or DR-1- driven luciferase
reporter activity.
Transcriptional activationin primary human hepatocytes
Although the rAoxPPRE promoter construct used in the
COS-1 transfection studies presented in Figure 4B was
derived from a natural mammalian DR-1 promoter
element, and was activated by CAR76, we further tested
the relative biological activities associated with the CAR1
A
B
Figure 7. Transient transfection assays. (A) Interplay of RXRa
homodimerization or heterodimerization with CAR in transactivation
of p(rAox-PPRE)4-tk-Luc in the absence or presence of RXRa ligand
9-cis-RA. COS-1 cells were transiently transfected with 100ng of
reporter construct, 50ng pCDNA3.1( ) or pCDNA3.1( )CAR 1,
50ng pCDNA3.1(þ) or pCDNA3.1(þ)RXRa or RXRa point mutants
(Y397A heterodimerization mutant; L430F homodimerization mutant)
and 10ng pRL-CMV (for transfection normalization) for 24h, then
treated with dimethyl sulfoxide (DMSO) solvent control or 100nM
9-cis-retinoic acid (RA) for 24h and assayed for luciferase activity.
(B) RXRa heterodimerization-dependent nuclear localization of
CAR 1, 76, 80 in COS-1 cells. COS-1 cells were transfected with
200ng pCDNA3.1( ) empty vector, CAR 1, 76 or 80 and 200ng
pCDNA3.1( ), RXRa, RXRaY397A (heterodimerization mutant) for
24–48h. Immunoﬂuorescent detection of CAR was performed as
described in the Experimental procedures section.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2185and CAR76 receptor isoforms in a more in vivo context. In
these latter assays, we infected primary cultures of human
hepatocytes with CAR lentiviral vectors that stably
integrate in the genome and direct cellular expression of
their respective receptor proteins. The results, from two
diﬀerent donors, are presented in Figure 10 and recapi-
tulate the data derived from the transfected COS-1 cell
experiments, indicating that CAR76 expression in hepa-
tocytes selectively activated expression of the endogenous
human PEPCK and HMGCS2 genes, both of which
contain DR-1 elements in their respective promoter
regions.
DISCUSSION
Previous studies of CAR variants demonstrated that not
all of the detected protein products were likely attributed
to alternatively spliced mRNA species (23). For examples,
A B
C
Figure 8. Transient transfection assays. (A)5 a-Androstan-3a-ol (androstanol) dose–response to optimize downregulation of CAR 1-dependent
transactivation of p(DR-4)3-tk-Luc. COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng pCDNA3.1( ),
pCDNA3.1( )CAR 1 or CAR76, 50ng pCDNA3.1( )PPARa and pCDNA3.1(þ)RXRa and 10ng pRL-CMV (for transfection normalization)
for 24h. Cells were then treated with dimethyl sulfoxide (DMSO) solvent control or 0.5, 1, 2, 4 or 8mM androstanol for 24h and assayed for
luciferase activity. (B)5 a-Androstan-3a-ol (androstanol) dose–response to optimize downregulation of CAR 1 and NCAR-dependent
transactivation of p(rAox-PPRE)4-tk-Luc. COS-1 cells were transiently transfected with 100ng of reporter construct, 50ng pCDNA3.1( ),
pCDNA3.1( )CAR 1 or CAR76, 50ng pCDNA3.1( )PPARa and pCDNA3.1(þ)RXRa and 10ng pRL-CMV (for transfection normalization) for
24h. Cells were then treated with DMSO solvent control or 0.5, 1, 2, 4 or 8mM androstanol for 24h and assayed for luciferase activity. (C) CITCO
dose–response to optimize re-activation of androstanol-antagonized CAR 1 and NCAR activity on p(rAox-PPRE)4-tk-Luc. COS-1 cells were
transiently transfected with 100ng of reporter construct 50ng pCDNA3.1( ), pCDNA3.1( )CAR 1, CAR 76, CAR 80 or pCDNA3.1( )PPARa
and pCDNA3.1(þ)RXRa and 10ng pRL-CMV (for transfection normalization) for 24h. Cells were then treated with DMSO solvent control, 2mM
androstanol, or co-treated with androstanol and increasing CITCO (0.3, 0.6, 1.25, 2.5mM) for 24h and assayed for luciferase activity.
2186 Nucleic Acids Research, 2007, Vol. 35, No. 7when COS-1 cells were transfected with plasmids expres-
sing various CAR mRNA splice variants, lower molecular
weight bands were consistently observed in SDS-PAGE
gels. Even upon expressing a CAR splice variant posses-
sing a partial deletion of exon 7, a proportionally lower
molecular weight band was detected. From these observa-
tions, we hypothesized that isoforms of CAR may arise
from the use of internal translation start sites. In the
present study, we identify new protein translational
variants of human CAR that diﬀer from those reported
previously. Speciﬁcally, we demonstrate that downstream
in-frame start codons produce N-terminally truncated
CAR variants (NCAR) from wild-type as well as
alternatively spliced mRNA transcripts. We determined
that CAR1, CAR76 and CAR80 proteins all functionally
activate luciferase reporter activity when driven by a
DR-1-type PPRE promoter element.
Speciﬁcally, since strong Kozak sequences (36,37) and
translational start sites were predicted from the use of
methionines at positions 1, 76, 80, 125, 128, 168 and 265,
we generated plasmid constructs with optimized Kozak
sequences to enable overexpression of CAR proteins from
each putative internal start site, and expressed these
constructs in transiently transfected COS-1 cells, in rabbit
reticulocyte lysates and in wheat germ in vitro translation
systems. In each case, protein bands were observed that
migrated with the expected molecular weights of the
truncated CAR76 and CAR80 proteins, and also
co-migrated with the more rapidly migrating bands
detectable upon co-expression of the full-length protein
encoded by the CAR1 template. A methionine to lysine
mutation at codon 1 (CAR M1K) abolished expression of
full-length CAR, but yielded prominent bands resulting
from CAR76 and CAR80 initiation. Similarly, when the
codons for amino acids 76 and 80 were mutated from
methionine to lysine in CAR1, the CAR76 and CAR80
bands were abolished, with proteins predicted to initiate at
amino acids 125 and 128 becoming readily detectable.
Dramatic sequential mutations of upstream methionines
always led to increases of protein expression from down-
stream internal translation start sites, supporting a model
of ‘cap-dependent’ translation of CAR mRNA, whereas
internal ribosome entry site (IRES)-dependent levels of
protein translation of NCAR would be expected to
proceed independently of mutations of upstream initiator
codons (38).
Others have reported that full-length mouse CAR can
activate a DR-2-type PPRE, but failed to show any
signiﬁcant transactivation on a DR-1 (13). Rather, mouse
CAR repressed ligand-dependent PPAR a/RXRa activity
on a DR-1 (13). A more recent study suggested that full-
length CAR binds to the promoters of the CYP7A1 and
PEPCK genes, decreasing their expression by competing
with the transcription factor HNF4 for binding to DR-1
elements (39). Perhaps the speciﬁc sequence context of a
DR-1 element may inﬂuence whether CAR exerts a
positive or negative eﬀect on transcription activity.
The reported discrepancies may also have resulted from
diﬀerences in the cell lines used or from the inclusion/
exclusion of RXRa co-transfection. It is interesting
that another laboratory reported that alternative splicing
of human CAR may result in an mRNA variant
that lacks the usual protein translational start site
in exon 2, instead enabling translation from an AUG
start codon in exon 1 (24). In this latter case, the use of an
alternative exon 1 translation initiation codon predicts
the inclusion of unique N-terminal amino acids that
are in-frame with amino acids encoded by exon 3.
These investigators also predicted CAR translation
from codons 125 and 128, rather than codons 76 and 80
AB
Figure 9. Electrophoretic mobility shift assays. (A) CAR 1 and CAR 76 binding to [
32P]NR1(DR-4) or [
32P]rAox-PPRE. COS-1 cells were transiently
transfected with pCDNA3.1( ), CAR 1 or CAR 76 and subjected to selection with 500mg/ml G418 to enrich a population of cells overexpressing
CAR 1 and CAR 76. Nuclear extracts were obtained from the CAR-expressing cells and used in EMSA as described in the Experimental procedures
section. (B) CAR 1 and PPARa binding to [
32P]NR1(DR-4) or [
32P]rAox-PPRE. COS-1 cells were transiently transfected with pCDNA3.1( ) CAR 1
or pCDNA3.1( )PPARa for 24h, nuclear extracts were obtained and EMSA performed as described in the Experimental procedures section.
Nucleic Acids Research, 2007, Vol. 35, No. 7 2187that we identify here as the actual start sites used to
generate NCARs possessing unique transcriptional
activities (24).
In our experiments, full-length CAR and the NCARs,
CAR76 and CAR80, exhibited constitutive activity on a
special DR-1 PPRE, and the receptor activities were
downregulated by treatment with the CAR inverse agonist
5a-androstan-3a-ol (androstanol). Co-treatment with
androstanol and the human CAR-speciﬁc agonist,
CITCO, completely restored CAR and NCAR activities
to constitutive levels. Transient co-expression of RXRa
variants and CAR or NCARs revealed that receptor
heterodimerization was the most important criterion for
gene promoter activation. In this respect, the RXRa AF-1
domain was not required for transactivation by the
NCARs, nor was RXRa’s AF-2 domain. When point-
mutated RXRa expression constructs were co-transfected
with the NCARs, the RXRa heterodimer-defective
variant, Y397A, completely ablated the ability of the
NCARs to activate a PPRE response element, yet the
Y397A RXRa could still homodimerize and function in
reporter transactivation. Conversely, a mutation of RXRa
that abolishes RXRa homodimerization, L430F, still
allowed for eﬃcient heterodimer formation with CAR
and the NCARs, reﬂected by subsequent reporter gene
activation, but eﬀectively inhibited RXRa homodimer
transactivation in the presence of chemical agonist.
Therefore, our results demonstrate that the lack of a
CAR-DNA-binding domain in a CAR-RXRa receptor
heterodimer does not inactivate the dimer’s transactiva-
tion function on a DR-1 or in a PPRE promoter context.
In fact, examples of classical nuclear receptors have been
reported previously that retain transactivation ability on
gene promoters without direct DNA-binding interactions,
including ER (40), the retinoic acid receptor (RAR)
(41) and the glucocorticoid receptor (42). In the latter
case, transgenic mice possessing DNA-binding defective
GRs were still viable and the modiﬁed receptors retained
functional ability to cross-talk with other transcrip-
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Figure 10. Lentiviral infections and real-time PCR analysis. (A) GFP expression in primary human hepatocytes infected with GFP-expressing
lentivirus. Pseudoviral particles were produced using pSIH1-H1-copGFP lentiviral vector, virus was concentrated and infections were conducted as
described in the Experimental procedures section. Images depict hepatocytes at 5 days post-infection in phase-contrast (100 ), and ﬂuorescence
microscopy (100 ). (B) Real-time PCR analysis of CAR, CYP2B6, PEPCK and HMGCS2 expression levels in primary human hepatocytes from two
diﬀerent donors infected with CAR1- and CAR76-expressing lentivirus. Pseudoviral particles expressing CAR1 and CAR76 in pCDH1-MCS1-EF1-
copGFP lentiviral vectors were produced and infections were performed as described in the Experimental procedures section. Four days post-
infection hepatocytes were harvested and RNA was isolated, converted to cDNA, subjected to real-time PCR and the data analyzed as described in
the Experimental procedures section. Each bar depicts the average relative fold expression of two PCR reactions from a single hepatocyte donor.
2188 Nucleic Acids Research, 2007, Vol. 35, No. 7as transrepression. For CAR, and perhaps for other
nuclear receptors as well, we predict that truncated forms
of the receptor may exhibit full or partial activation
function, or even repression, and that the spectrum of
these activities may manifest on an altered repertoire of
response elements. Speciﬁcally, we propose a new model
of CAR DBD-independent transactivation, whereby only
the RXRa component of the heterodimer binds directly to
a DR-1-containing PPRE, tethered to CAR or NCARs
(CAR76 or CAR80), with functional contributions
from the CAR AF-2 domain providing the basis for
co-activator recruitment and subsequent gene transactiva-
tion function. This type of heterodimer–DNA interaction
is in striking contrast to that reported previously for
the APYLT-CAR splice variant, a variant that possesses a
5 aa insertion in the receptor’s dimerization interface (14).
For the latter receptor, the RXRa DBD, rather than
the APYLT-CAR DBD, is expendable for transcriptional
activation, implying a model invoking direct contact of
only the CAR portion of the dimer with DNA, not
the RXRa component (14). Taken together, along with
the recently identiﬁed phosphorylation modiﬁcations
that impact the ability of CAR to translocate (43), it is
becoming clear that the post-transcriptional regulation
of CAR expression is an important means of generating a
diversity of receptor modalities that likely function to
enhance its complex role as a receptor integrator of
xenobiotic and endobiotic sensing in mammalian cells.
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